IDEAYA Biosciences (NASDAQ:IDYA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of IDEAYA Biosciences (NASDAQ:IDYA) from a hold rating to a buy rating in a research note issued to investors on Sunday.

A number of other equities research analysts have also issued reports on the stock. Stephens reiterated an “overweight” rating and set a $45.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Royal Bank Of Canada increased their price objective on IDEAYA Biosciences from $38.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. New Street Research set a $30.00 target price on IDEAYA Biosciences in a report on Tuesday, October 21st. Guggenheim started coverage on IDEAYA Biosciences in a research note on Thursday, September 18th. They set a “buy” rating and a $50.00 target price for the company. Finally, The Goldman Sachs Group upped their price target on IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Tuesday, October 21st. Fourteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.50.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $32.01 on Friday. The company has a market cap of $2.81 billion, a P/E ratio of -17.21 and a beta of 0.14. The stock has a 50-day moving average of $27.77 and a two-hundred day moving average of $23.96. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $33.64.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.45. The business had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. On average, analysts anticipate that IDEAYA Biosciences will post -3.07 EPS for the current fiscal year.

Institutional Investors Weigh In On IDEAYA Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in IDEAYA Biosciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock valued at $83,417,000 after purchasing an additional 14,535 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of IDEAYA Biosciences by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company’s stock worth $44,424,000 after buying an additional 33,286 shares during the last quarter. Fiera Capital Corp lifted its position in shares of IDEAYA Biosciences by 20.0% during the 3rd quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock worth $50,011,000 after buying an additional 305,698 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of IDEAYA Biosciences by 4.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock valued at $26,025,000 after buying an additional 50,000 shares in the last quarter. Finally, Candriam S.C.A. grew its position in shares of IDEAYA Biosciences by 10.8% in the 3rd quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock valued at $27,563,000 after buying an additional 98,567 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.